Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

Launched by TATA MEMORIAL CENTRE · Feb 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called memantine can help protect memory and thinking skills in young patients undergoing a specific type of radiation therapy known as craniospinal irradiation (CSI). The trial will involve participants aged 5 to 39 who are scheduled to receive CSI, which may be combined with other treatments. Some patients will receive memantine along with their standard treatment, while others will only receive the standard treatment. The researchers will then compare the memory and thinking abilities of both groups after the radiation therapy to see if memantine makes a difference.

To participate, individuals must be within the age range and meet certain health criteria, such as being able to provide consent and having a good performance status (which means they are able to carry out daily activities). Participants will undergo tests to assess their cognitive abilities during the trial. If you or someone you know fits this description and is interested in being part of the trial, it could be an opportunity to contribute to important research that might help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age at irradiation: 5 to 39 years
• • Planned for CSI (with or without boost dose) with or without systemic chemotherapy
• • Informed consent or assent taken
• • Karnofsky Performance Status / Lansky Performance Status ≥ 60
• Exclusion Criteria:
• • Re-irradiation
• • Prior exposure to memantine
• • Inability to undergo Wechsler test